Among patients with systemic lupus erythematosus (SLE) there is an increased risk of haematological malignancies, especially non-Hodgkin lymphoma. However, the association of SLE with aggressive CD3 negative natural killer (NK)-cell leukaemia has not been reported so far. We present a case of a 39-year-old woman with SLE, aggressive NK-cell leukaemia and tuberous sclerosis complex. The prior probability of developing the combination of these three rare diseases by coincidence is extremely low (<10−13). Possible underlying immunological, genetic and toxic/environmental pathways are discussed.
PetterssonTPukkalaETeppoLFrimanC. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis1992; 51: 437–439.
2.
OgataAKitanoMFukamizuMHamanoTSanoH. Increased serum interleukin-18 in a patient with systemic lupus erythematosus and T-cell large granular lymphocytic leukemia. Mod Rheumatol2004; 14: 267–270.
3.
BernatskySRamsey-GoldmanRJosephL. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis2014; 73: 138–142.
4.
Ramsey-GoldmanRBernatskySClarkeA. Dialogue: what can we learn about the relationship between systemic lupus erythematosus and haematological malignancies from linking disease registries?Lupus Sci Med2014; 1: e000068–e000068.
NorthrupHKruegerDA. International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol2013; 49: 243–254.
7.
FernandezDPerlA. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?Discov Med2010; 9: 173–178.
8.
OsborneJPFryerAWebbD. Epidemiology of tuberous sclerosis. Ann NY Acad Sci1991; 615: 125–127.
9.
DanchenkoNSatiaJAAnthonyMS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus2006; 15: 308–318.
10.
Pons-EstelGJAlarconGSScofieldLReinlibLCooperGS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthr Rheum2010; 39: 257–268.
11.
LimaM. Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis. Orphanet J Rare Dis2013; 8: 95–95.
12.
van den ReekJMvan LumigPPJanssenM. Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol2014; 28: 27–33.
13.
PerkovicSBasic-KindaSGasparovicV. Epstein–Barr virus-negative aggressive natural killer-cell leukaemia with high P-glycoprotein activity and phosphorylated extracellular signal-regulated protein kinases 1 and 2. Hematol Rep2012; 4: e16–e16.
14.
BernatskySBoivinJFJosephL. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum2005; 52: 1481–1490.
15.
LeblancFZhangDLiuXLoughranTP. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol2012; 8: 787–801.
16.
SuzukiRSuzumiyaJNakamuraS. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia2004; 18: 763–770.
17.
WongCKHoCYLiEKLamCW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus2000; 9: 589–593.
18.
KarubeKNakagawaMTsuzukiS. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood2011; 118: 3195–3204.
19.
McPheeCGSprouleTJShinDM. MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis. J Immunol2011; 187: 4695–4704.
20.
HanlonPAvenellAAucottLVickersMA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein–Barr virus and systemic lupus erythematosus. Arthritis Res Ther2014; 16: R3–R3.
21.
DraborgAHJacobsenSWestergaardM. Reduced response to Epstein–Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Sci Med2014; 1: e000015–e000015.
22.
KoYHParkSKimKKimSJKimWS. Aggressive natural killer cell leukemia: is Epstein–Barr virus negativity an indicator of a favorable prognosis?Acta Haematol2008; 120: 199–206.
23.
InokiKCorradettiMNGuanKL. Dysregulation of the TSC–mTOR pathway in human disease. Nat Genet2005; 37: 19–24.
24.
SinghNBirkenbachMCazaTPerlACohenPL. Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol2013; 19: 134–137.
25.
SchadeAEPowersJJWlodarskiMWMaciejewskiJP. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood2006; 107: 4834–4840.
26.
KawadaJItoYIwataS. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein–Barr virus-associated T and natural killer cell lymphoma cells. Clin Cancer Res2014; 20: 5412–5422.
27.
SteelmanLSAbramsSLWhelanJ. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia2008; 22: 686–707.
28.
O'SheaJJHollandSMStaudtLM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med2013; 368: 161–170.
KooGCTanSYTangT. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov2012; 2: 591–597.
31.
JerezAClementeMJMakishimaH. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood2012; 120: 3048–3057.
32.
RemmersEFPlengeRMLeeAT. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med2007; 357: 977–986.
